S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$219.32
-3.85 (-1.73%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$218.50
$225.96
50-Day Range
$192.77
$226.43
52-Week Range
$141.41
$228.89
Volume
976,493 shs
Average Volume
1.72 million shs
Market Capitalization
$103.77 billion
P/E Ratio
52.85
Dividend Yield
0.45%
Beta
0.66
30 days | 90 days | 365 days | Advanced Chart
Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.


Zoetis logo

About Zoetis

Zoetis, Inc. discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.

Headlines

Zoetis (NYSE:ZTS) Hits New 12-Month High at $228.89
November 22, 2021 |  americanbankingnews.com
Zoetis (NYSE:ZTS) Releases FY 2021 Earnings Guidance
November 18, 2021 |  americanbankingnews.com
Morgan Stanley Begins Coverage on Zoetis (NYSE:ZTS)
November 18, 2021 |  americanbankingnews.com
Zoetis (NYSE:ZTS) Reaches New 1-Year High at $220.86
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
11,300
Year Founded
2012

Sales & Book Value

Annual Sales
$6.68 billion
Cash Flow
$4.89 per share
Book Value
$9.89 per share

Profitability

Net Income
$1.64 billion
Pretax Margin
31.54%

Debt

Price-To-Earnings

Miscellaneous

Free Float
472,322,000
Market Cap
$103.77 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
10/28/2021
Last Earnings
11/04/2021
Today
11/26/2021
Dividend Payable
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/15/2022

Social Links


MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

196th out of 1,392 stocks

Pharmaceutical Preparations Industry

82nd out of 670 stocks

Analyst Opinion: 1.4Community Rank: 5.0Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Zoetis (NYSE:ZTS) Frequently Asked Questions

Is Zoetis a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis
or view top-rated stocks.

How has Zoetis' stock price been impacted by COVID-19 (Coronavirus)?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZTS shares have increased by 68.4% and is now trading at $219.32.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Zoetis?

Zoetis saw a decrease in short interest in October. As of October 15th, there was short interest totaling 2,960,000 shares, a decrease of 19.8% from the September 30th total of 3,690,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is currently 2.2 days. Currently, 0.6% of the shares of the company are sold short.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Zoetis
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Thursday, November, 4th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.15. The company had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.93 billion. Zoetis had a net margin of 26.02% and a trailing twelve-month return on equity of 52.17%. The company's quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.10 EPS.
View Zoetis' earnings history
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, October 14th. Stockholders of record on Friday, October 29th will be given a dividend of $0.25 per share on Wednesday, December 1st. This represents a $1.00 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Thursday, October 28th.
View Zoetis' dividend history
.

Is Zoetis a good dividend stock?

Zoetis pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.45%. Zoetis does not yet have a strong track record of dividend growth. The dividend payout ratio of Zoetis is 24.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 19.38% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided EPS guidance of $4.620-$4.670 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.550. The company issued revenue guidance of $7.70 billion-$7.75 billion, compared to the consensus revenue estimate of $7.70 billion.

What price target have analysts set for ZTS?

7 Wall Street analysts have issued 12-month price objectives for Zoetis' stock. Their forecasts range from $180.00 to $264.00. On average, they anticipate Zoetis' share price to reach $219.13 in the next year. This suggests that the stock has a possible downside of 0.1%.
View analysts' price targets for Zoetis
or view top-rated stocks among Wall Street analysts.

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Kristin C. Peck, Chief Executive Officer & Director
  • Roxanne Lagano, Chief Human Resources Officer (LinkedIn Profile)
  • Wetteny Joseph, CFO, EVP & Head-Business Development
  • Catherine Ann Knupp, Executive VP, President-Research & Development
  • Wafaa Mamilli, Chief Information & Digital Officer

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.22%), Alliancebernstein L.P. (3.64%), State Farm Mutual Automobile Insurance Co. (3.62%), Polen Capital Management LLC (2.02%), Capital World Investors (1.91%) and Geode Capital Management LLC (1.81%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Morgan Stanley, State Farm Mutual Automobile Insurance Co., Goldman Sachs Group Inc., The Manufacturers Life Insurance Company , Lord Abbett & CO. LLC, Marshall Wace LLP, and Man Group plc. Company insiders that have sold Zoetis company stock in the last year include Gregory Norden, Heidi C Chen, Kristin C Peck, Robert Edward Kelly, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
or view top insider-selling stocks.

Which institutional investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Nordea Investment Management AB, BlackRock Inc., Renaissance Technologies LLC, Deutsche Bank AG, Alliancebernstein L.P., Arrowstreet Capital Limited Partnership, and CI Investments Inc..
View insider buying and selling activity for Zoetis
or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $219.32.

How much money does Zoetis make?

Zoetis has a market capitalization of $103.77 billion and generates $6.68 billion in revenue each year. The company earns $1.64 billion in net income (profit) each year or $4.15 on an earnings per share basis.

How many employees does Zoetis have?

Zoetis employs 11,300 workers across the globe.

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..

When was Zoetis founded?

Zoetis was founded in 2012.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

Where are Zoetis' headquarters?

Zoetis is headquartered at 10 Sylvan Way, Parsippany NJ, 07054.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at (973) 822-7000, via email at [email protected], or via fax at 302-655-5049.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.